Treatment-related toxicity
| Toxic events . | Number of patients (N = 22), n (%) . | ||||
|---|---|---|---|---|---|
| Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | All grades . | |
| Total number of toxic events | 144 | 6 | 61 | 33 | 244 |
| Patients with ≥1 toxic events | 9 (40.9) | 1 (4.5) | 8 (36.4) | 3 (13.6) | 21 (95.5) |
| Injection site reaction | 9 (40.9) | 1 (4.5) | — | — | 10 (45.5) |
| Skin induration | 6 (27.3) | 1 (4.5) | — | — | 7 (31.8) |
| Fatigue | 7 (31.8) | — | — | — | 7 (31.8) |
| Pruritus | 5 (22.7) | 1 (4.5) | — | — | 6 (27.3) |
| Lymphocyte count decreased | — | — | 4 (18.2) | 2 (9.1) | 6 (27.3) |
| Neutrophil count decreased | — | — | 4 (18.2) | 2 (9.1) | 6 (27.3) |
| White blood cell count decreased | — | — | 5 (22.7) | 1 (4.5) | 6 (27.3) |
| Platelet count decreased | — | — | 3 (13.6) | 1 (4.5) | 4 (18.2) |
| Pain | 3 (13.6) | — | — | — | 3 (13.6) |
| Pain in extremity | 3 (13.6) | — | — | — | 3 (13.6) |
| Flushing | 2 (9.1) | — | 1 (4.5) | — | 3 (13.6) |
| Dry skin | 2 (9.1) | — | — | — | 2 (9.1) |
| Rash maculopapular | 2 (9.1) | — | — | — | 2 (9.1) |
| Bone pain | — | 1 (4.5) | 1 (4.5) | — | 2 (9.1) |
| Muscular weakness | 2 (9.1) | — | — | — | 2 (9.1) |
| Skin infection | 2 (9.1) | — | — | — | 2 (9.1) |
| Upper respiratory tract infection | 2 (9.1) | — | — | — | 2 (9.1) |
| Urinary tract infection | 1 (4.5) | 1 (4.5) | — | — | 2 (9.1) |
| Headache | 2 (9.1) | — | — | — | 2 (9.1) |
| Toxic events . | Number of patients (N = 22), n (%) . | ||||
|---|---|---|---|---|---|
| Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | All grades . | |
| Total number of toxic events | 144 | 6 | 61 | 33 | 244 |
| Patients with ≥1 toxic events | 9 (40.9) | 1 (4.5) | 8 (36.4) | 3 (13.6) | 21 (95.5) |
| Injection site reaction | 9 (40.9) | 1 (4.5) | — | — | 10 (45.5) |
| Skin induration | 6 (27.3) | 1 (4.5) | — | — | 7 (31.8) |
| Fatigue | 7 (31.8) | — | — | — | 7 (31.8) |
| Pruritus | 5 (22.7) | 1 (4.5) | — | — | 6 (27.3) |
| Lymphocyte count decreased | — | — | 4 (18.2) | 2 (9.1) | 6 (27.3) |
| Neutrophil count decreased | — | — | 4 (18.2) | 2 (9.1) | 6 (27.3) |
| White blood cell count decreased | — | — | 5 (22.7) | 1 (4.5) | 6 (27.3) |
| Platelet count decreased | — | — | 3 (13.6) | 1 (4.5) | 4 (18.2) |
| Pain | 3 (13.6) | — | — | — | 3 (13.6) |
| Pain in extremity | 3 (13.6) | — | — | — | 3 (13.6) |
| Flushing | 2 (9.1) | — | 1 (4.5) | — | 3 (13.6) |
| Dry skin | 2 (9.1) | — | — | — | 2 (9.1) |
| Rash maculopapular | 2 (9.1) | — | — | — | 2 (9.1) |
| Bone pain | — | 1 (4.5) | 1 (4.5) | — | 2 (9.1) |
| Muscular weakness | 2 (9.1) | — | — | — | 2 (9.1) |
| Skin infection | 2 (9.1) | — | — | — | 2 (9.1) |
| Upper respiratory tract infection | 2 (9.1) | — | — | — | 2 (9.1) |
| Urinary tract infection | 1 (4.5) | 1 (4.5) | — | — | 2 (9.1) |
| Headache | 2 (9.1) | — | — | — | 2 (9.1) |
For toxicity grading, National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0 was used. Table is ordered by decreasing proportions of total patients having at least 1 toxic event. Toxic events occurring in only 1 patient were excluded.
N, total number of patients; n, number of patients meeting specified criteria; TEAE, treatment-emergent adverse event.